Faq / Support

As any other test used to make a critical medical decision concerning the diagnosis or the treatment of cancer, OncoDEEP has to be ordered by your physician/oncologist/medical professional. If you could benefit from being tested with OncoDEEP, consult your treating physician and discuss with him about this opportunity.
Your treating physician will take care about everything. If you have requested and received a free information kit, just give it to him: it will be used for the shipment of your tumor sample and contains all instructions and paperwork to be completed.
Formalin-fixed, paraffin-embedded tissues are very stable in time at room temperature. So if there is not enough tissue remaining from an earlier biopsy, there is no need to run a new biopsy to get a more recent sample.
Cancer is a complex multigenic disease and has become a model for the use of biomarkers in drug prescription. These biomarkers have installed the concept of personalized medicine in the daily practice of oncologists. OncoDEEP is the perfect tool to help your physician to characterization of it and choose of the best treatment regimen based on this tumor description. Your oncologist will hold all the cards to choose not only the best approved treatment but also promising treatments which are still into development, which have been specifically designed to treat tumor harboring the same biomarkers.
Oncodeep has been designed to be used on any solid tumor cancer, e.g. lung, breast, colorectal, stomach and liver cancers. You may benefit of OncoDEEP, whatever you’re already under treatment or have already received a drug prescription. While OncoDEEP is commonly used by patients who have already been treated by standard treatments without success, or who are facing very aggressive cancer forms or cancer with metastases, we have observed that more and more oncologists/patients are requesting this test very early in the development of the disease.
OncoDNA takes seriously the trust you place in us. To prevent unauthorized access or disclosure, to maintain data accuracy, and to ensure the appropriate use of information, OncoDNA uses a range of reasonable physical, technical, and administrative measures to safeguard your Personal Information, in accordance with current technological and industry standards. As you’re using this web interface, we ask you to be responsible for safeguarding your password and other authentication information you use to access your account. We encourage you to read our full Privacy Statement for additional information on our privacy and security practices.
The price mentioned on OncoSHARE is the price of the services when it gets out of OncoDNA’s doors. Logistics of the samples, management of the payment, currency conversion issues, interaction with the oncologist in his/her own language, specific consent filling, … are extra costs which need to be passed on to the final customer in his/her own country.

Cancer is a highly complex disease. Historically, cancer has been named after the organ of origin of the tumor; and most cancers are retaining specific characteristics of this origin. But looking at the molecular level, many cancers look alike and major cancer pathways are active (or can be activated) in all cancer types. For example, two breast cancers can be more different at the molecular level (and then in term of therapy regimen) than a breast cancer and an ovarian cancer can be. That’s why OncoDEEP is looking, in a non-supervised way, to more than 60 cancer actionable genes.

When oncologists order an OncoDEEP testing for the first time, it’s usually related to patients who have already received treatments from guidelines and which have failed; the same guidelines that are only requiring single gene testing for the prescription of an approved drug for a specific cancer type. For those patients, OncoDEEP has now so many times demonstrated that a) those failed guidelines could have been detected earlier, speeding up the choice of the right treatment by a closer observation of suspected failure; b) in many complex cancer cases, those “single gene” or “specific pathway” are not always enough to fully characterize the patients and provide them with the most efficient treatment.

Using OncoDEEP is providing the most cost-effective molecular characterization of the tumor of the patient and by doing so, taking stock of the prescription portfolio available, not just the drugs that are approved (because if those are often enough, it’s not always the case) but also for those which are approved for other indications or those which are still under development (and have already proven their efficacy in these trials). These last two opportunities are sometimes the only potentially efficient treatment for a patient with complex cancer and you can’t find them just looking at “specific pathway”.

The interest of Oncotype DX® Breast Cancer Assays related to treatment only concerns ER-positive, HER2-negative invasive breast cancer patients. The test calculates a risk score, based on gene expression profiling, to help determine the magnitude of tamoxifen benefit for an individual patient. As it is a statistical score based on gene signature, the assay needs to be validated in a validation clinical study.

OncoDEEP questions both genetic variants (using Next Generation Sequencing) and protein biomarkers (using molecular pathology tests) and is not just specific to breast cancer or specific to a single breast cancer subtype but can address all breast cancers and other cancer types with solid tumors (Lung, Glioma, Colorectal, ….). It helps determine treatment options amongst all available cancer drugs based on the comprehensive molecular characterization of the tumor. Conclusions delivered by OncoDEEP are relying only on strong clinical trial evidence for each marker.

MammaPrint is the first FDA-cleared assay that tests for breast cancer recurrence rates. So it measures the risk of distant recurrence following surgery. For assistance in their therapeutic decision making, and as mentioned on Agendia’s website, physicians will need other clinical criteria and pathology tests to be performed…

OncoDEEP does not measure any risk of recurrence. Its only goal is to help physicians with treatment options proposals based on a complete molecular characterization of the tumor of the patient. OncoDEEP is expert in helping physicians with therapeutic decisions.

Formalin-fixed, paraffin-embedded tissues are very stable in time at room temperature. So if there is not enough tissue remaining from an earlier biopsy, there is no need to run a new biopsy to get a more recent sample.
Oncodeep has been designed to be used on any solid tumor cancer, e.g. lung, breast, colorectal, stomach and liver cancers. You may benefit of OncoDEEP, whatever you’re already under treatment or have already received a drug prescription. While OncoDEEP is commonly used by patients who have already been treated by standard treatments without success, or who are facing very aggressive cancer forms or cancer with metastases, we have observed that more and more oncologists/patients are requesting this test very early in the development of the disease.

The price depends on the test you have selected. The simplest way to proceed to payment is using credit card payment. You may also pay by wire transfer using these Bank Account Information.

Address

OncoDNA SA
25,Avenue George Lemaître
B-6041 Gosselies
BELGIUM - EUROPE

Payment information

IBAN : BE72 3631 1253 7016
BIC : BBRUBEBB

The price mentioned on OncoSHARE is the price of the services when it gets out of OncoDNA’s doors. Logistics of the samples, management of the payment, currency conversion issues, interaction with the oncologist in his/her own language, specific consent filling, … are extra costs which need to be passed on to the final customer in his/her own country.

We are working with local agent/distributor who are visiting physician/oncologist to increasing awareness about OncoDEEP/OncoSHARE. If you’re a healthcare professional and have questions in relationship with OncoDEEP distribution, feel free to tell us and we will put you in contact with your local distributor.

OncoDEEP, OncoTRACE & OncoSHARE : Personalize, Monitor and Connect

Sign up for free

2014 © OncoSHARE by OncoDNA SA